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Background: Daptomycin non-susceptible enterococci (DNSE) are emerging as an important cause of healthcare-
associated infection, however little is known about the epidemiology of DNSE. At the University of Iowa Hospitals
and Clinics (UIHC) an increase in the frequency of patients infected and/or colonized with DNSE has occurred. The
goals of this study were to evaluate potential factors associated with the development of DNSE colonization and/or
infection and to compare the characteristics of patients with prior daptomycin exposure to those without prior
daptomycin exposure.
Methods: The study is a retrospective case-series involving all patients with DNSE infection and/or colonization at
UIHC, a 734-bed academic referral center, from June 1, 2005 to June 1, 2011.
Results: The majority of patients with DNSE colonization and/or infection had prior daptomycin exposure (15 of 25;
60%), a concomitant gastrointestinal process (19 of 25; 76%), or were immunosuppressed (21 of 25; 84%). DNSE
infection was confirmed in 17 of 25 (68%) patients, including 9 patients with bacteremia. Twelve of 17 (71%)
patients with DNSE infection had prior daptomycin exposure, including 7 of 9 (78%) patients with bacteremia.
Compared to patients without prior daptomycin exposure, patients with prior daptomycin exposure were less likely
to harbor E. faecalis (0% vs. 33%; p = 0.019). A high proportion of patients (10 of 25; 40%) died during their
hospitalizations. Most enterococcal isolates were E. faecium (86%), and were vancomycin-resistant (72%). Molecular
typing revealed a diverse population of DNSE.
Conclusions: Prior daptomycin exposure, immunosuppression, and/or a concomitant gastrointestinal process, may
be associated with the development of DNSE. PFGE revealed a diverse population of DNSE, which along with both
increasing numbers of DNSE detected yearly and increasing annual rates of daptomycin usage, suggests the
emergence of DNSE under antimicrobial pressure.
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Enterococci are Gram-positive, facultative anaerobes
that reside primarily in the gastrointestinal tract. They
are generally considered to be of low virulence, but are
associated with serious bloodstream, joint, wound, car-
diac, urinary, and gastrointestinal infections [1]. Entero-
cocci are often multi-drug resistant, and are responsible
for the transmission of various genetic resistance ele-
ments to other bacteria, including vancomycin resistance* Correspondence: jcstorm79@gmail.com; birgir-johannsson@uiowa.edu
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reproduction in any medium, provided the orto other enterococci as well as Staphylococcus aureus
[2,3].
Daptomycin is a lipopeptide antibiotic currently
approved by the Food and Drug Administration (FDA)
for the treatment of complicated infection of skin and/or
subcutaneous tissue as well as bacteremia and right-
sided endocarditis due to S. aureus [3]. In addition, it is
often used in the treatment of infections due to
vancomycin-resistant enterococci (VRE), although it is
not approved for these conditions [3,4]. Shortly after its
FDA approval in 2003, reports of infections due to dap-
tomycin non-susceptible enterococci (DNSE) emerged
and cases have been described both with and withouttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Storm et al. Antimicrobial Resistance and Infection Control 2012, 1:19 Page 2 of 7
http://www.aricjournal.com/content/1/1/19prior daptomycin exposure [4-9]. Despite this, little is
known about the potential causes or risk factors for the
development of DNSE colonization or infection. Here,
we report the findings at our institution, The University
of Iowa Hospitals and Clinics (UIHC), over a 6-year
period (June 1, 2005 through June 1, 2011).
Methods
The UIHC is a 734-bed, academic, and major referral
center for the state of Iowa and surrounding region, with
over 28,000 inpatient admissions and 900,000 outpatient
visits each year. The UIHC Institutional Review Board
granted approval for this study.
By searching our clinical microbiology laboratory data-
base, we identified all DNSE isolates from the time the
first clinical isolate was identified (June 1, 2005) to June
1, 2011. An extensive review of the medical record was
performed for all patients with DNSE isolated from any
source. Infection due to DNSE was defined as isolation
from a sterile source, or isolation from a non-sterile
source if accompanied by documented symptoms or
signs of infection and/or treating clinician explicit diag-
nosis. Daptomycin usage during the study period was
determined yearly by dividing the number of inpatients
receiving daptomycin (based on discharge billing data)
by the total number of patient discharges for a given year.
P-values were calculated with the use of the chi-square.
At UIHC, daptomycin susceptibility testing is per-
formed on all enterococcal isolates (both VSE and VRE)
according to standard Clinical and Laboratory Standards
Institute (CLSI) method [10], with daptomycin non-
susceptibility defined as a daptomycin minimum in-
hibitory concentration (MIC)> 4 micrograms/mL. All
enterococcal isolates not susceptible to daptomycin upon
initial testing were re-tested using the CLSI broth micro-
dilution and Etest methods. All available DNSE isolates
underwent pulsed-field gel electrophoresis (PFGE) to as-
sess for genetic relatedness, using previously described
methods [11]. PFGE patterns were analyzed using Bionu-
merics software (Applied Maths, Kortrijk, Belgium). The
unweighted pair group method with arithmetic averages
and DICE coefficient (0.5% optimization, 1.0% position
tolerance) were used for dendrogram construction. A
similarity coefficient of 0.8 was used to define PFGE
types, and subtypes were defined as isolates sharing in-
distinguishable banding patterns.
Results
The median age of patients with DNSE was 52.2 years,
with 14 of 25 (56%) being female (Table 1). DNSE was
identified in 25 patients and found in 32 clinical samples
from 4 specimen sources including; blood (9 patients; 12
isolates), urine (12 patients; 14 isolates), peritoneal fluid
or intra-abdominal abscess (3 patients; 4 isolates), andwounds (2 patients; 2 isolates). One patient had DNSE
identified from both urine and blood (Table 1). Multiple
isolates from the same patient were always of the same
species, PFGE type or subtype, and had an identical anti-
microbial susceptibility pattern.
Infection due to DNSE was confirmed by both labora-
tory and chart review in 17 of 25 (68%) patients. In the
remaining 8 patients, DNSE was isolated from urine
alone and represented colonization based on the absence
of documented clinical symptoms and/or negative urin-
alysis. A bloodstream infection was identified in 9
patients, a genitourinary infection such as UTI, pyelo-
nephritis, or kidney abscess in 3 patients, bacterial peri-
tonitis in 3 patients, and a skin and soft tissue infection
and/or osteomyelitis in 2 patients.
A concomitant gastrointestinal or intra-abdominal
process was identified in 19 of 25 (76%) patients, includ-
ing Clostridium difficile infection, graft-versus-host-dis-
ease of the gut, neutropenic enterocolitis/perforation,
traumatic bowel perforation, bowel ischemia, bacterial
peritonitis, ascending cholangitis, gastroparesis, pyelo-
nephritis and/or kidney abscess, or other gastrointestinal
surgery with complications. Twenty-one patients (84%)
were immunosuppressed, including: 12 (48%) with
underlying cancer and/or ongoing chemotherapy; 12
(48%) with diabetes mellitus (including 4 with an asso-
ciated malignancy, 2 requiring hemodialysis for end-
stage renal disease, 2 requiring immunosuppressive
therapy for prior kidney-pancreas transplants, and 1 with
hip osteomyelitis); and 1 patient requiring dialysis for
end-stage renal disease due to hypertension. In-hospital
mortality of patients with DNSE infection or colonization
was high, occurring in 10 of 25 patients (40%).
Daptomycin exposure was confirmed in 15 of 25 (60%)
patients prior to the isolation of DNSE. Of these, 10 of
15 (67%) had DNSE isolated during treatment with dap-
tomycin after receiving an average of 13.9 days of ther-
apy (range 3–40 days). The remaining 5 patients had
recently received daptomycin with an average drug-free
interval of 7.8 days (range 3–14 days) prior to DNSE iso-
lation. In patients with prior daptomycin exposure, the
total days of daptomycin therapy in the year prior to iso-
lation of DNSE varied between 5–67 days, with a mean
of 20.9 days and median of 16 days. Ten patients had no
documented daptomycin exposure at our institution,
and no evidence in their medical records that they
received daptomycin prior to admission at UIHC. How-
ever, detailed records of care prior to UIHC admission
were not always available and therefore daptomycin ex-
posure could not be completely excluded in these cases.
Of patients with prior daptomycin exposure, 8 of 15
(53%) were female, compared to 6 of 10 (60%) of patients
without prior daptomycin exposure (Table 2). Compared
to patients without prior daptomycin exposure, patients
Table 1 Clinical characteristics of patients with DNSE colonization or infection
Year, Age,
Sex
Past Medical History Total Days of
Daptomycin Exposure
Species Source Reason for Admission
and/or Complications
2011
55F MDS, SCT 5 E. faecium Blood, urine Neutropenia, GVHD of gut
55F ALL, BMT, DM, PVD No E. faecium Blood Neutropenia, CDI
58F Gynecological malignancy 9 E. faecium Blood GI inflammation due to metastatic disease
59F AML 19 E. faecium Blood Neutropenia, appendicitis
51F AML, SCT 29 E. faecium Urinea Neutropenia, colitis
2010
74F MDS, SBO, CHF, Pulmonary Htn 10 E. faecium Urinea Small bowel resection, sepsis
80F CAD, COPD, PVD No E. faecalis Urinea Bowel ischemia after surgery
42 M DM, bipolar disorder 12 E. faecium Wound, lumbar Chronic lumbar abscess
56F AML, SCT, DM 67 E. faecium Blood Neutropenia, sigmoid colon perforation
2009
50F AML, SCT 20 E. faecium Urinea Neutropenia, GVHD of gut, colitis
50 M DM, Hip SSTI/osteomyelitis 19 E. faecium Wound, hip Hip SSTI / osteomyelitis
49 M CAD, CHF, COPD, ESRD/HD, PVD 52 Not able to
identify
Peritoneal fluid GI perforation, peritonitis
37 M Kidney-pancreas transplant, DM 11 E. faecium Blood Recurrent cholangitis
49 M Kidney-pancreas transplant, DM 12 E. faecium Blood Intraabdominal abscess after surgery
2008
39 M Hydrocephalus, VPS 25 E. faecium Peritoneal fluid GI perforation following MVA
61F DM, endometrial malignancy No E. faecium Urine Pelvic exenteration, kidney abscess
78 M CAD, CKD, CVA, DM No E. faecium Urinea Septic arthritis due viridans streptococci
57 M Urinary bladder malignancy No E. faecium Peritoneal fluid Pelvic abscess after surgery
2007
59 M MDS, BMT 8 E. faecium Blood Neutropenic fever, GVHD of gut
59F DM, ESRD/HD, VHD 16 E. faecium Urinea Cryptococcal meningitis
2006
6F Recurrent UTI No Not Available Urine UTI
46F Cholangitis, DM, ESRD/HD No E. faecalis Blood Recurrent polymicrobial cholangitis
62 M CAD, COPD No Not available Urinea Lumbar pain and sciatica
2005
38 M DM, metastatic malignancy of colon No Not available Urine Chemotherapy, neutropenia, pyelonephritis
35F DM, gastroparesis No Not available Urinea Recurrent gastroparesis
Patient characteristics, past medical history, daptomycin exposure history (total days in prior year), isolate species, isolate source, and abbreviated reason for
admission and/or complications arising during index admission for the 25 patients identified to be colonized or infected with DNSE during the study period.
NOTE:
a – Represents DNSE colonization.
Abbreviations: ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; BMT = bone marrow transplant; CAD = coronary artery disease; CDI =
Clostridium difficile infection; CHF = congestive heart failure; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CVA = cerebro-vascular
accident; DM = diabetes mellitus; ESRD/HD = end stage renal disease requiring hemodialysis; GI = gastrointestinal; GVHD = graft versus host disease; MDS =
myelodysplastic syndrome; MVA = motor vehicle accident; PVD = peripheral vascular disease; SBO = small bowl obstruction; SCT = stem cell transplant; SSTI = skin
and soft tissue infection; UTI = urinary tract infection; VHD = valvular heart disease; VPS = ventriculoperitoneal shunt; Pulmonary Htn = pulmonary hypertension.
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bor E. faecalis (0% vs. 33%; p = 0.019). In patients with
DNSE and prior daptomycin exposure, there was a non-
significant trend toward having a bloodstream isolate
(47% vs. 20%; p = 0.174), a history of immunosuppressionfrom any cause (93% vs. 70%; p = 0.119), and death (53%
vs. 20%; p = 0.096).
The number of patients with DNSE colonization or in-
fection at UIHC increased from 2.33 cases per year for
the time period 2005–2007 to 4.33 cases per year for the









Number of Isolates 15 (60%) 10 (40%) –
Age 52.5 51.8 –
Sex – no (%)
-Female 8/15 (53%) 6/10 (60%) 0.742
Isolate
-E. faecium 14 (93%) 4 (67%) 0.115
-E. faecalis 0 (0%) 2 (33%) 0.019
-Species Not Identified 1 (7%) 0 (0%) –
-Isolate Not Availablea 0 4 –
Source
-Bloodb 7 (47%) 2 (20%) 0.174
-Urineb 5 (33%) 7 (70%) 0.072
-Peritoneal Fluid 2 (13%) 1 (10%) 0.802
-Wound 2 (13%) 0 (0%) 0.229
-Colonizationc 4 (27%) 4 (40%) 0.484
Past Medical History
-Diabetes 6 (40%) 6 (60%) 0.327
-ESRD/Dialysis 2 (13%) 1 (10%) 0.802
-Cancer/Chemotherapyd 8 (53%) 4 (40%) 0.513
-History of Transplant 2 (13%) 0 (0%) 0.229
-CVDe 3 (20%) 4 (40%) 0.275
-Lung Diseasef 2 (13%) 2 (20%) 0.656
GI or Intra-abdominal Processg 12 (80%) 7 (70%) 0.566
Immunosuppressionh 14 (93%) 7 (70%) 0.119
Deathi 8 (53%) 2 (20%) 0.096
Note:
* - All P values were calculated with the use of the chi-square test.
a – Four isolates were not available for species identification.
b – One patient with DNSE and prior daptomycin exposure had DNSE isolated
from both blood and urine.
c – All colonizing isolates were obtained from urine of patients without
symptoms and/or negative urinalysis.
d – includes all patients with acute lymphoblastic leukemia, acute
myelogenous leukemia, myelodysplastic syndrome, bone marrow transplant,
stem cell transplant, solid organ tumor, and those undergoing chemotherapy.
e – includes all patients with coronary artery disease, congestive heart failure,
cerebro-vascular accident, peripheral vascular disease, and valvular heart
disease.
f – includes all patients with chronic obstructive pulmonary disease and
pulmonary hypertension.
g – includes all patients with Clostridium difficile infection, graft-versus-host
-disease of the gut, neutropenic enterocolitis/perforation, traumatic bowel
perforation, bowel ischemia, bacterial peritonitis, ascending cholangitis,
gastroparesis, pyelonephritis and/or kidney abscess, or other gastrointestinal
surgery with complications.
h – includes all patients with any cancer or undergoing chemotherapy,
diabetes mellitus, ESRD/HD, organ transplant.
i – Hospital and/or thirty-day mortality from any cause.
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cases were identified in the first 6 months of 2011 alone
– as many as had been noted over any 12-month period
previously. Rates of daptomycin usage at UIHC increased
during the study period as well, from approximately 0.2%
of inpatients in 2005 receiving daptomycin to 0.9% in
2011 (Figure 1).
Twenty-one patients had enterococcal isolates avail-
able for species identification. Of these, eighteen patients
(86%) had E. faecium, and two (10%) had E. faecalis
(Table 3). Vancomycin resistance was common, occur-
ring in DNSE isolates from 18 of 25 patients (72%), in-
cluding 16 of 18 (89%) E. faecium isolates. Ampicillin
resistance was detected in DNSE isolates from 18 of 25
patients (72%), and in 17 of 18 (94%) E. faecium isolates.
Linezolid resistance was uncommon, occurring in only 1
DNSE isolate from 21 patients. Linezolid susceptibility
was not performed for 4 patient’s isolates, as they were
not available for further susceptibility testing.
PFGE revealed significant genetic heterogeneity, with
16 PFGE types and 24 subtypes represented among the
29 patient isolates available for typing (results not
shown). Multiple isolates from the same patient were al-
ways of the same type or subtype. There were only four
instances in which more than one patient shared the
same PFGE type with the most common PFGE type
shared among 4 patients. In only one instance did two
patients share the same PFGE subtype.
Discussion
In the past 20 years, there have been increases in both
the frequency of enterococcal infections and in rates of
enterococcal drug resistance [12]. VRE is now the third
most common cause of nosocomial bloodstream infec-
tion [13], and compared to vancomycin-susceptible en-
terococci (VSE), is associated with increased healthcare
costs, morbidity, and mortality [14]. Enterococci are of
particular concern due to their ability to spread drug re-
sistance to other bacteria via mobile genetic elements,
resulting in beta-lactam, aminoglycoside, and glycopep-
tide resistance.
Vancomycin resistance in both Enterococcus species
and S. aureus is well described, mediated by van-type
plasmids from VRE [15]. In S. aureus, daptomycin resist-
ance is possibly mediated by several mechanisms, in-
cluding cell wall thickening and charge alterations
[16,17]. The exact mechanism of daptomycin resistance
in enterococci is not entirely known, but may be related
to alterations in cell membrane charge, thickness, and
permeability via mutations to cell membrane cardiolipin
synthetase and/or other proteins involved in regulating
phospholipid metabolism or the stress response to anti-
microbial agents [18,19]. Daptomycin exposure is likely
to be essential to the development of resistance in
Figure 1 Number of patients with colonization/infection due to daptomycin non-susceptible enterococci (solid bars; left vertical axis),
and percentage of all discharged in-patients prescribed daptomycin during their hospital stay (solid line; right vertical axis) for each
study year. Information for 2011 based on information for the first 6 months of calendar year.
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mentioned studies and our finding of a high rate (60%)
of confirmed prior daptomycin exposure in patients har-
boring a DNSE isolate as well as the genetic heterogen-
eity noted on PFGE.
Little is known regarding risk factors or causes for the
development of DNSE. Prior daptomycin exposure has
been described in case reports of DNSE bacteremia; how-
ever cases describing resistance developing de novo have
been reported [5-9]. In the largest case series to date of
DNSE bacteremia, performed at Memorial Sloan-Kettering
Cancer Center during a 3 year period (2007–2009), the
authors found prior daptomycin exposure to be an uncom-
mon event with only 2 of 18 (11%) patients having had
documented daptomycin exposure prior to the develop-
ment of DNSE bacteremia [7]. These findings are in con-
trast to our observation at UIHC, where during a similar
time period (2005–2011), the majority of patients with
DNSE colonization or infection had confirmed daptomycin
exposure prior to the isolation of a non-susceptible isolate
(any clinical sample; 15 of 25 or 60%, blood stream 7 of 9
or 78%). This may be an under-estimate however, as the
rate of confirmed daptomycin exposure in the era ofTable 3 Antimicrobial resistance profile of enterococcal isolat
Enterococcus species Proportion of iso
Daptomycin Van
(%)
E. faecium (n = 18) 100
E. faecalis (n = 2) 100
Other (n = 5)a 100
NOTE:
a – One Enterococcus isolate was identified as non-faecium / non-faecalis, and four
b – Of the 21 patient isolates available for susceptibility testing; only the non-faeciuelectronic order entry (February 2009 to present) at UIHC
was substantially higher than before its institution (86% vs.
27%). A recent case series and case control study compar-
ing DNSE in patients either with or without prior dapto-
mycin exposure showed results similar to ours, with prior
daptomycin exposure in 59%, immunosuppression in 78%,
an average age of 58.9 years, E. faecium in 78%, and death
in 44% [8,9].
Since daptomycin was introduced for clinical use in
2003, significant increases in rates of resistance or MIC
creep have not been noted in the United States with an
overall prevalence of DNSE estimated at< 1% [4,20,21].
However in other areas, in particular Asia and parts of
Europe, resistance rates may be significantly higher than
in the US [4]. Over the past 6 years at our institution,
we have noticed an increase in the absolute number of
patients colonized or infected with DNSE, which has
taken place in the setting of increasing rates of daptomy-
cin usage during the same period (Figure 1).
In the US, approximately 90% of DNSE isolates are
also resistant to vancomycin [20,21]. And like VRE, dap-
tomycin non-susceptible isolates are more often E. fae-
cium than E. faecalis (88% vs. 9%) [4]. At our institutiones to selected antimicrobial agents by species






were not available for species identification or linezolid susceptibility testing.
m / non-faecalis Enterococcus isolate was resistant to linezolid.
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main daptomycin susceptible, and the observed species
identification and susceptibility of the daptomycin non-
susceptible isolates observed in our study align with that
reported nationally (Table 3) [4,20].
In addition to prior daptomycin exposure, several find-
ings in patients with DNSE colonization or infection at
our institution are worth noting and may provide clues
to potential factors associated with the development of
DNSE. The majority of patients were immunosuppressed
(21 of 25; 84%) or had a concomitant gastrointestinal in-
flammatory process (19 of 25; 76%). Also, a genitourin-
ary process was noted in 3 of 25 (12%) patients. These
results are not surprising given that enterococci com-
monly colonize the gastrointestinal and genitourinary
tracts, and that the majority of these patients had risk
factors for the development of gastrointestinal or geni-
tourinary complications or infections.
Molecular typing revealed that daptomycin non-
susceptibility emerged among diverse strains of entero-
cocci, with patient-to-patient transmission of DNSE
occurring less often. This suggests that cases of DNSE
were likely the result of mutations in patient’s own flora
under antimicrobial pressure, as opposed to patient-to-
patient transfer of an outbreak or common strain. Finally,
in-hospital mortality of patients with DNSE infection or
colonization was high, at 40%. We are not aware of out-
come studies related to the presence of daptomycin
non-susceptibility versus daptomycin susceptibility in
enterococcal colonization or infection.Conclusion
To our knowledge, this is the largest study to date to
evaluate potential factors associated with the develop-
ment of DNSE colonization and/or infection and to com-
pare the characteristics of patients with prior daptomycin
exposure to those without prior daptomycin exposure.
We found that prior daptomycin exposure, immunosup-
pression, or a concomitant gastrointestinal or intra-
abdominal process, preceded the development of DNSE.
During the study period, we noticed an increase in the
number of cases of DNSE yearly that corresponded to in-
creasing annual rates of daptomycin usage at our institu-
tion. Molecular typing revealed a diverse population of
isolates suggesting the development of resistance under
antimicrobial pressure. Also, a high percentage of
patients with DNSE colonization or infection died during
their hospitalization. Limitations of this study include its
retrospective nature and small number of patients. Fu-
ture case–control or prospective studies comparing
patients with and without DNSE and/or prior daptomy-
cin exposure would be helpful in better identifying fac-
tors associated with DNSE infection and/or colonization.Competing interest
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